Abstract

Intrahepatic cholangiocarcinomas (ICC) are rare primary liver tumors. In few cases, they may invade nearby organs and present as extrahepatic growths, leading to poor prognosis. We report a case of a 78-year-old man who presented with fatigue. An upper gastrointestinal endoscopy was performed to find a cause for his anemia, which showed a submucosal tumor with delle at the lesser curvature of the gastric cardia. A computed tomography revealed a low-density tumor of diameter 70 mm at the cardia. It appeared to infiltrate the liver directly. We performed lateral hepatectomy, proximal gastrectomy and lymphadenectomy. The pathological findings revealed an ICC with gastric infiltration. Although adjuvant chemotherapy was administered, 12 months postoperatively, the patient developed pain and multiple bone metastases for which palliative radiation was initiated. The guidelines for lymphadenectomy and adjuvant chemotherapy in such cases are unclear. Appropriate regional lymphadenectomy and adjuvant chemotherapy can improve the prognosis of such patients.

INTRODUCTION

Intrahepatic cholangiocarcinoma (ICC) is a rare primary liver tumor, and accounts for 4.8% of all primary liver cancers in Japan [1]. Occasionally, an ICC presents as an extrahepatic growth. In few cases, ICC may invade nearby organs. Herein, we present a case of ICC with gastric infiltration that appeared like a submucosal tumor (SMT).

In upper gastrointestinal endoscopy, the tumor looked like a submucosal tumor with delle at the lesser curvature of the cardia (arrow).
Figure 1

In upper gastrointestinal endoscopy, the tumor looked like a submucosal tumor with delle at the lesser curvature of the cardia (arrow).

In abdominal enhanced computed tomography, a slightly low-density tumor of about 70 mm in diameter at the cardia (arrow) was seen. It appeared to infiltrate into the liver directly. (A: plane; B: axial image in the artery phase; C: coronal image in the artery phase; D: sagittal image in the artery phase)
Figure 2

In abdominal enhanced computed tomography, a slightly low-density tumor of about 70 mm in diameter at the cardia (arrow) was seen. It appeared to infiltrate into the liver directly. (A: plane; B: axial image in the artery phase; C: coronal image in the artery phase; D: sagittal image in the artery phase)

CASE REPORT

A 78-year-old man visited a hospital for fatigue. He underwent an upper gastrointestinal (GI) endoscopy for anemia, and was diagnosed with a gastric SMT. He was referred to our hospital for further treatment. His family history was unremarkable. His past history included atrial fibrillation, right cerebral infarction and hypertension. His physical examination was unremarkable.

On investigating, his hemoglobin was 10 g/dl, and tumor markers, carcinoembryonic antigen and carbohydrate antigen 19-9 (CA 19-9), were elevated to 12.5 ng/ml and 94.3 U/ml, respectively. Tests for Hepatitis B and C viruses were negative. His upper GI endoscopy showed SMT with delle at the lesser curvature of the cardia (Fig. 1). A computed tomography (CT) showed a slightly low-density tumor of 70 mm in diameter at the cardia (Fig. 2). It appeared to infiltrate into the liver directly. We diagnosed it as gastric SMT (suspected GI stromal tumor) with liver infiltration.

The patient was taken up for surgery. Intraoperatively, the tumor was located in the stomach wall at the cardia and was invading the liver directly (Fig. 3). We performed a lateral hepatectomy by the Glissonean pedicle ligation method, proximal gastrectomy and lymphadenectomy. The operation time was 3 h and 19 min, and intraoperative blood loss was 260 ml. The resected specimen showed a white solid tumor of dimensions 80 mm × 55 mm × 44 mm. It showed a little ulcerative change in the mucosal layer (Fig. 4). Most of the tumor originating from the liver was found under the gastric mucosa (Figs 4 and 5). Microscopically, a poorly differentiated adenocarcinoma with unclear duct formation was detected (Fig. 6). The non-tumor area of the liver was normal. Immunostaining showed that the tumor was positive for AE1/AE3 and negative for CK20, CK7, CD34, c-kit, CD56, synaptophysin and chromogranin A (Fig. 6). Based on these findings, our diagnosis was ICC with gastric infiltration, and we categorized it as pT4, pN0, cM0, Stage IIIB as per the eighth edition of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) [2]. The immediate postoperative course was uneventful, and the patient was discharged on postoperative Day 16. Three months after the surgery, he was administered S-1 orally as adjuvant chemotherapy. However, 12 months after the surgery, multiple bone metastases were detected on CT. He underwent palliative radiation to relieve pain and prevent pathological fractures.

Intraoperative findings showed that the tumor was located in the stomach wall of the cardia and was invading into the liver directly (A, arrow). Lateral hepatectomy, proximal gastrectomy, and lymphadenectomy were performed (B).
Figure 3

Intraoperative findings showed that the tumor was located in the stomach wall of the cardia and was invading into the liver directly (A, arrow). Lateral hepatectomy, proximal gastrectomy, and lymphadenectomy were performed (B).

The resected specimen showed a white solid tumor continued from the left lateral liver to the stomach wall (A, arrow). Most of the tumor was found under the gastric mucosa (B, arrow). The tumor looked like a submucosal tumor with delle (C, arrowhead).
Figure 4

The resected specimen showed a white solid tumor continued from the left lateral liver to the stomach wall (A, arrow). Most of the tumor was found under the gastric mucosa (B, arrow). The tumor looked like a submucosal tumor with delle (C, arrowhead).

The tumor originated from the liver and showed extrahepatic growth (arrow).
Figure 5

The tumor originated from the liver and showed extrahepatic growth (arrow).

Pathological and immunostaining findings. (A) Hematoxylin–Eosin staining (×20): A poorly differentiated adenocarcinoma with unclear duct formation was detected. (B) AE1/AE3 staining (×20): positive. (C) CK20 staining (×20): negative. (D) CK7 staining (×20): negative. (E) CD34 staining (×20): negative. (F) c-kit staining (×20): negative. (G) CD56 staining (×20): negative. (H) synaptophysin staining (×20): negative. (I) chromogranin A staining (×20): negative.
Figure 6

Pathological and immunostaining findings. (A) Hematoxylin–Eosin staining (×20): A poorly differentiated adenocarcinoma with unclear duct formation was detected. (B) AE1/AE3 staining (×20): positive. (C) CK20 staining (×20): negative. (D) CK7 staining (×20): negative. (E) CD34 staining (×20): negative. (F) c-kit staining (×20): negative. (G) CD56 staining (×20): negative. (H) synaptophysin staining (×20): negative. (I) chromogranin A staining (×20): negative.

DISCUSSION

ICC has a poor prognosis and an overall 5-year survival of <10% for all patients [3]. Unfortunately, 80–85% of patients with ICC present at an unresectable stage of the disease, with no potential for cure [4]. Kang et al. [5] indicated in a multivariate analysis that independent risk factors for tumor recurrence and patient survival were multiple tumors; CA, 19-9 > 200 U/mL; tumor size, > 5 cm; direct invasion to extrahepatic structures; and lymph node metastases. Although a surgery, such as hepatectomy, is considered the first option of treatment for ICC, the role of lymph node excision is still unclear, with no clear guidelines [6]. Giorgio et al. [6] report that routine regional lymphadenectomy is the most recent therapeutic strategy for ICC because the incidence of lymph node metastases is 40% for ICC. Nozaki et al. [7] suggested that regional lymphadenectomy should be performed in consideration with tumor location and the two main lymphatic drainage routes: one through the hepatoduodenal ligament and other through the cardiac portion of the stomach. If the tumor is located in the right lobe, lymphadenectomy in the former route may be necessary, and if it is located in the left lobe such as in our case, lymphadenectomy in both routes may be necessary. However, since our case was misdiagnosed as gastric SMT, we performed lymphadenectomy only in one route. Bartsch et al. [8] studied 102 cases of hepatectomy for ICC in a single center. Out of these 102, six had visceral infiltration—two in the diaphragm, one in adrenal gland, one in pericardium, one in duodenum and one in colon. They also reported that patients with visceral infiltration had a significantly shorter overall survival than patients without it (14.9 vs. 23.1 months) [8].

Table 1

Clinicopathological features of resected intrahepatic cholangiocarcinoma with visceral infiltration reported in the literature

Operative procedureLDVisceral
infiltration
Pathological
diagnosis
Tumor size
(cm)
CA19–9
(U/ml)
Adjuvant
chemotherapy
Survival after surgery
Left hepatectomy, Caudate lobectomy
Total gastrectomy, Partial diaphragmectomy
+StomachWell differentiated
AC
5.5 × 57510+
Tegafur
Not described
Left hepatectomy
Hemigastrectomy
+StomachAC
with sarcomatous elements
7.7WNLNDDead due to metastases
5 months
Right hepatectomy, Right adrenalectomy
Caval resection and reconstruction
NDRight AGModerately differentiated
AC
6.5 × 5.5WNLNDAlive without recurrence
22 months
Right hepatectomy
Partial diaphragmectomy
DiaphragmPoorly differentiated
AC
7 × 6 × 323NDAlive without recurrence
24 months
Left hepatectomy, Caudate lobectomy
Partial gastrectomy
+StomachModerately differentiated
AC
6.4 × 5.8 × 517NDND
Right hepatectomy, Partial diaphragmectomy
Right lower partial pneumonectomy
NDLung
Diaphragm
Adenosquamous
cell carcinoma
11 × 8NDNDDead due to metastasis
6 months
Right hepatic trisegmentectomy+GallbladderWell differentiated
AC
11 × 9 × 6>12000NDAlive without recurrence
7 months
Left hepatectomy, Caudate lobectomy
Distal gastrectomy
+StomachModerately differentiated
AC
5151.7+
GEM
Alive without recurrence
18 months
Right hepatectomy
Right hemicolectomy
+TCPoorly differentiated
AC
12 × 10WNL+
Tegaful-urasil
Alive after treatment for brain metastasis
84 months
Right hepatectomy, Partial diaphragmectomy
Right lower partial pneumonectomy
NDLung
Diaphragm
AC9 × 6.5 × 61518NDAlive with recurrence
3 months
Right hepatectomy, Partial diaphragmectomy
Right adrenalectomy, Right nephrectomy
NDDiaphragm, Right AG
Right kidney
Poorly differentiated
AC
9 × 7.215.9NDDead due to recurrence
6 months
Extended right hepatectomy, Caudate lobectomy
Partial diaphragmectomy, Right adrenalectomy
+Right AGModerately differentiated
AC
10222+
GEM
Alive without recurrence
12 months
Lateral hepatectomy, Total gastrectomy
Partial pancreatectomy
+Stomach
Pancreas
Moderately differentiated
AC
99899Alive with recurrence
8 months
Central bisegmentectomy
Partial diaphragmectomy
NDDiaphragmPoorly differentiated
AC
4WNLNDAlive after treatment for diaphragm recurrence
29 months
Partial resection of the S4
Partial duodenectomy
+DuodenumModerately differentiated
AC
3.3WNL+
GEM
Alive after treatment for liver recurrence
21 months
Subsegmentectomy of the S4a and S5
Partial colectomy
+TC
Gallbladder
Moderately differentiated
AC
7 × 4.8 × 43605.5+
GEM
Alive without recurrence
9 months
Extended cholecystectomy, Partial gastrectomy
Partial duodenectomy, Partial colectomy
+Stomach, Duodenum
TC, Gallbladder
Poorly differentiated
AC
938+
GEM/Cisplatin
Dead due to recurrence
9 months
Lateral hepatectomy
Proximal gastrectomy
+StomachPoorly differentiated
AC
8 × 5.5 × 4.494.3+
S-1
Alive with recurrence
12 months
Operative procedureLDVisceral
infiltration
Pathological
diagnosis
Tumor size
(cm)
CA19–9
(U/ml)
Adjuvant
chemotherapy
Survival after surgery
Left hepatectomy, Caudate lobectomy
Total gastrectomy, Partial diaphragmectomy
+StomachWell differentiated
AC
5.5 × 57510+
Tegafur
Not described
Left hepatectomy
Hemigastrectomy
+StomachAC
with sarcomatous elements
7.7WNLNDDead due to metastases
5 months
Right hepatectomy, Right adrenalectomy
Caval resection and reconstruction
NDRight AGModerately differentiated
AC
6.5 × 5.5WNLNDAlive without recurrence
22 months
Right hepatectomy
Partial diaphragmectomy
DiaphragmPoorly differentiated
AC
7 × 6 × 323NDAlive without recurrence
24 months
Left hepatectomy, Caudate lobectomy
Partial gastrectomy
+StomachModerately differentiated
AC
6.4 × 5.8 × 517NDND
Right hepatectomy, Partial diaphragmectomy
Right lower partial pneumonectomy
NDLung
Diaphragm
Adenosquamous
cell carcinoma
11 × 8NDNDDead due to metastasis
6 months
Right hepatic trisegmentectomy+GallbladderWell differentiated
AC
11 × 9 × 6>12000NDAlive without recurrence
7 months
Left hepatectomy, Caudate lobectomy
Distal gastrectomy
+StomachModerately differentiated
AC
5151.7+
GEM
Alive without recurrence
18 months
Right hepatectomy
Right hemicolectomy
+TCPoorly differentiated
AC
12 × 10WNL+
Tegaful-urasil
Alive after treatment for brain metastasis
84 months
Right hepatectomy, Partial diaphragmectomy
Right lower partial pneumonectomy
NDLung
Diaphragm
AC9 × 6.5 × 61518NDAlive with recurrence
3 months
Right hepatectomy, Partial diaphragmectomy
Right adrenalectomy, Right nephrectomy
NDDiaphragm, Right AG
Right kidney
Poorly differentiated
AC
9 × 7.215.9NDDead due to recurrence
6 months
Extended right hepatectomy, Caudate lobectomy
Partial diaphragmectomy, Right adrenalectomy
+Right AGModerately differentiated
AC
10222+
GEM
Alive without recurrence
12 months
Lateral hepatectomy, Total gastrectomy
Partial pancreatectomy
+Stomach
Pancreas
Moderately differentiated
AC
99899Alive with recurrence
8 months
Central bisegmentectomy
Partial diaphragmectomy
NDDiaphragmPoorly differentiated
AC
4WNLNDAlive after treatment for diaphragm recurrence
29 months
Partial resection of the S4
Partial duodenectomy
+DuodenumModerately differentiated
AC
3.3WNL+
GEM
Alive after treatment for liver recurrence
21 months
Subsegmentectomy of the S4a and S5
Partial colectomy
+TC
Gallbladder
Moderately differentiated
AC
7 × 4.8 × 43605.5+
GEM
Alive without recurrence
9 months
Extended cholecystectomy, Partial gastrectomy
Partial duodenectomy, Partial colectomy
+Stomach, Duodenum
TC, Gallbladder
Poorly differentiated
AC
938+
GEM/Cisplatin
Dead due to recurrence
9 months
Lateral hepatectomy
Proximal gastrectomy
+StomachPoorly differentiated
AC
8 × 5.5 × 4.494.3+
S-1
Alive with recurrence
12 months

AC: adenocarcinoma, AG: adrenal grand, GEM: gemcitabine, LD: lymph node dissection, ND: not described, RFA: radiofrequency ablation, TACE: transcatheter arterial chemoembolization, TC: transverse colon, WNL: within normal limit

Table 1

Clinicopathological features of resected intrahepatic cholangiocarcinoma with visceral infiltration reported in the literature

Operative procedureLDVisceral
infiltration
Pathological
diagnosis
Tumor size
(cm)
CA19–9
(U/ml)
Adjuvant
chemotherapy
Survival after surgery
Left hepatectomy, Caudate lobectomy
Total gastrectomy, Partial diaphragmectomy
+StomachWell differentiated
AC
5.5 × 57510+
Tegafur
Not described
Left hepatectomy
Hemigastrectomy
+StomachAC
with sarcomatous elements
7.7WNLNDDead due to metastases
5 months
Right hepatectomy, Right adrenalectomy
Caval resection and reconstruction
NDRight AGModerately differentiated
AC
6.5 × 5.5WNLNDAlive without recurrence
22 months
Right hepatectomy
Partial diaphragmectomy
DiaphragmPoorly differentiated
AC
7 × 6 × 323NDAlive without recurrence
24 months
Left hepatectomy, Caudate lobectomy
Partial gastrectomy
+StomachModerately differentiated
AC
6.4 × 5.8 × 517NDND
Right hepatectomy, Partial diaphragmectomy
Right lower partial pneumonectomy
NDLung
Diaphragm
Adenosquamous
cell carcinoma
11 × 8NDNDDead due to metastasis
6 months
Right hepatic trisegmentectomy+GallbladderWell differentiated
AC
11 × 9 × 6>12000NDAlive without recurrence
7 months
Left hepatectomy, Caudate lobectomy
Distal gastrectomy
+StomachModerately differentiated
AC
5151.7+
GEM
Alive without recurrence
18 months
Right hepatectomy
Right hemicolectomy
+TCPoorly differentiated
AC
12 × 10WNL+
Tegaful-urasil
Alive after treatment for brain metastasis
84 months
Right hepatectomy, Partial diaphragmectomy
Right lower partial pneumonectomy
NDLung
Diaphragm
AC9 × 6.5 × 61518NDAlive with recurrence
3 months
Right hepatectomy, Partial diaphragmectomy
Right adrenalectomy, Right nephrectomy
NDDiaphragm, Right AG
Right kidney
Poorly differentiated
AC
9 × 7.215.9NDDead due to recurrence
6 months
Extended right hepatectomy, Caudate lobectomy
Partial diaphragmectomy, Right adrenalectomy
+Right AGModerately differentiated
AC
10222+
GEM
Alive without recurrence
12 months
Lateral hepatectomy, Total gastrectomy
Partial pancreatectomy
+Stomach
Pancreas
Moderately differentiated
AC
99899Alive with recurrence
8 months
Central bisegmentectomy
Partial diaphragmectomy
NDDiaphragmPoorly differentiated
AC
4WNLNDAlive after treatment for diaphragm recurrence
29 months
Partial resection of the S4
Partial duodenectomy
+DuodenumModerately differentiated
AC
3.3WNL+
GEM
Alive after treatment for liver recurrence
21 months
Subsegmentectomy of the S4a and S5
Partial colectomy
+TC
Gallbladder
Moderately differentiated
AC
7 × 4.8 × 43605.5+
GEM
Alive without recurrence
9 months
Extended cholecystectomy, Partial gastrectomy
Partial duodenectomy, Partial colectomy
+Stomach, Duodenum
TC, Gallbladder
Poorly differentiated
AC
938+
GEM/Cisplatin
Dead due to recurrence
9 months
Lateral hepatectomy
Proximal gastrectomy
+StomachPoorly differentiated
AC
8 × 5.5 × 4.494.3+
S-1
Alive with recurrence
12 months
Operative procedureLDVisceral
infiltration
Pathological
diagnosis
Tumor size
(cm)
CA19–9
(U/ml)
Adjuvant
chemotherapy
Survival after surgery
Left hepatectomy, Caudate lobectomy
Total gastrectomy, Partial diaphragmectomy
+StomachWell differentiated
AC
5.5 × 57510+
Tegafur
Not described
Left hepatectomy
Hemigastrectomy
+StomachAC
with sarcomatous elements
7.7WNLNDDead due to metastases
5 months
Right hepatectomy, Right adrenalectomy
Caval resection and reconstruction
NDRight AGModerately differentiated
AC
6.5 × 5.5WNLNDAlive without recurrence
22 months
Right hepatectomy
Partial diaphragmectomy
DiaphragmPoorly differentiated
AC
7 × 6 × 323NDAlive without recurrence
24 months
Left hepatectomy, Caudate lobectomy
Partial gastrectomy
+StomachModerately differentiated
AC
6.4 × 5.8 × 517NDND
Right hepatectomy, Partial diaphragmectomy
Right lower partial pneumonectomy
NDLung
Diaphragm
Adenosquamous
cell carcinoma
11 × 8NDNDDead due to metastasis
6 months
Right hepatic trisegmentectomy+GallbladderWell differentiated
AC
11 × 9 × 6>12000NDAlive without recurrence
7 months
Left hepatectomy, Caudate lobectomy
Distal gastrectomy
+StomachModerately differentiated
AC
5151.7+
GEM
Alive without recurrence
18 months
Right hepatectomy
Right hemicolectomy
+TCPoorly differentiated
AC
12 × 10WNL+
Tegaful-urasil
Alive after treatment for brain metastasis
84 months
Right hepatectomy, Partial diaphragmectomy
Right lower partial pneumonectomy
NDLung
Diaphragm
AC9 × 6.5 × 61518NDAlive with recurrence
3 months
Right hepatectomy, Partial diaphragmectomy
Right adrenalectomy, Right nephrectomy
NDDiaphragm, Right AG
Right kidney
Poorly differentiated
AC
9 × 7.215.9NDDead due to recurrence
6 months
Extended right hepatectomy, Caudate lobectomy
Partial diaphragmectomy, Right adrenalectomy
+Right AGModerately differentiated
AC
10222+
GEM
Alive without recurrence
12 months
Lateral hepatectomy, Total gastrectomy
Partial pancreatectomy
+Stomach
Pancreas
Moderately differentiated
AC
99899Alive with recurrence
8 months
Central bisegmentectomy
Partial diaphragmectomy
NDDiaphragmPoorly differentiated
AC
4WNLNDAlive after treatment for diaphragm recurrence
29 months
Partial resection of the S4
Partial duodenectomy
+DuodenumModerately differentiated
AC
3.3WNL+
GEM
Alive after treatment for liver recurrence
21 months
Subsegmentectomy of the S4a and S5
Partial colectomy
+TC
Gallbladder
Moderately differentiated
AC
7 × 4.8 × 43605.5+
GEM
Alive without recurrence
9 months
Extended cholecystectomy, Partial gastrectomy
Partial duodenectomy, Partial colectomy
+Stomach, Duodenum
TC, Gallbladder
Poorly differentiated
AC
938+
GEM/Cisplatin
Dead due to recurrence
9 months
Lateral hepatectomy
Proximal gastrectomy
+StomachPoorly differentiated
AC
8 × 5.5 × 4.494.3+
S-1
Alive with recurrence
12 months

AC: adenocarcinoma, AG: adrenal grand, GEM: gemcitabine, LD: lymph node dissection, ND: not described, RFA: radiofrequency ablation, TACE: transcatheter arterial chemoembolization, TC: transverse colon, WNL: within normal limit

In the eighth edition of the AJCC/UICC, T4 is defined as ‘tumor involving local extrahepatic structures by direct invasion’ [2]. To the best of our knowledge, resected ICCs with visceral infiltration have been reported only in three cases in English literature and in 14 cases in Japanese literature (Table 1). The median age of these patients was 63.5 years (range: 41–85). The median size of the tumor was 7.9 cm (range: 3.3–12), and except for one case, the size of the tumor was larger than 5 cm (94%). In six cases, CA 19-9 was over 200 U/L. In eight cases, adjuvant chemotherapy was administered—four, used gemcitabine; one, gemcitabine and cisplatin; one, tegafur; one, tegaful-urasil; and one, S-1. Visceral infiltration was noted for seven in the diaphragm; five, stomach; three, duodenum; three, transverse colon; three, gallbladder; three, lung; two, right adrenal gland; one, right kidney; and one, pancreas (some patients had visceral infiltration in more than one organ). Among the five cases of stomach infiltration, two showed SMT with delle on upper GI endoscopy. Lymphadenectomy was performed in 11 cases (61%). Within 6 months after surgery, three patients died from recurrence.

Like for lymph node excision, no clear guidelines exist for administration of adjuvant chemotherapy for such cases. However, adjuvant chemotherapy with Capecitabine can improve the overall survival in patients with resected biliary tract cancer [3].

Only a few cases of resected ICCs with visceral infiltration have been reported in the literature. Therefore, we believe, our case report can help to understand the characteristic features of these rare cases and, as a result, improve their prognosis.

CONFLICTS OF INTEREST STATEMENT

None declared.

References

1.

Masatoshi
 
K
,
Namiki
 
I
,
Shoji
 
K
,
Norihiro
 
K
,
Michiie
 
S
,
Shuichiro
 
S
, et al.  
Report of the 20th nationwide follow-up survey of primary liver cancer in Japan
.
Hepatol Res
 
2020
;
50
:
15
46
.

2.

Amin
 
MB
. American Joint Committee on Cancer, American Cancer Society. In:
AJCC Cancer Staging Manual
, Vol.
xvii
, Eighth edn.
Chicago, IL
:
American Joint Committee on Cancer, Springer
,
2017
,
1024
.

3.

John
 
NP
,
Richard
 
PF
,
Daniel
 
HP
,
Hassan
 
ZM
,
Raj
 
P
,
Darius
 
M
, et al.  
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicenter, phase 3 study
.
Lancet Oncol
 
2019
;
20
:
663
73
.

4.

Jensen
 
CCT
,
Natalie
 
GC
,
Nancy
 
NB
,
Alex
 
K
,
Calvin
 
HLL
.
Surgical Management of Intrahepatic Cholangiocarcinoma – a population-based study
.
Ann Surg Oncol
 
2008
;
15
:
600
8
.

5.

Kang
 
SH
,
Hwang
 
S
,
Lee
 
YJ
,
Kim
 
KH
,
Ahn
 
CS
,
Moon
 
DB
, et al.  
Prognostic comparison of the 7th and 8th editions of the American joint committee on cancer staging system for intrahepatic cholangiocarcinoma
.
J Hepatobiliary Pancreat Sci
 
2018
;
25
:
240
8
.

6.

Giorgio
 
E
,
Gian
 
LG
,
Matteo
 
R
,
Walter
 
FG
,
Matteo
 
C
,
Andrea
 
G
, et al.  
The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy
.
Ann Surg
 
2004
;
239
:
202
9
.

7.

Yoshihiro
 
N
,
Masayuki
 
Y
,
Iwao
 
I
,
Yuzo
 
Y
,
Nobuhiro
 
O
,
Hideki
 
F
, et al.  
Reconsideration of the lymph node metastasis pattern (N factor) from intrahepatic cholangiocarcinoma using the international union against cancer TNM staging system for primary liver carcinoma
.
Cancer
 
1998
;
83
:
1923
9
.

8.

Fabian
 
B
,
Janine
 
B
,
Maria
 
HL
,
Irene
 
S
,
Stefan
 
H
,
Hauke
 
L
.
Visceral infiltration of intrahepatic cholangiocarcinoma is most prognostic after curative resection – retrospective cohort study of 102 consecutive liver resections from a single center
.
Int J Surg
 
2018
;
55
:
193
200
.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com